Dr. John Kastelein is professor of medicine, chairman of the department of vascular medicine, and holds the Strategic Chair of Genetics in Cardiovascular Disease at the Academic Medical Center of the University of Amsterdam. Dr. Kastelein is the principal investigator of the ENHANCE trial on the effectiveness of Vytorin.

Dr. Kastelein received his medical degree from the University of Amsterdam, trained in internal medicine at the Academic Medical Center of the University of Amsterdam, and trained in lipidology and molecular biology at the University of British Columbia in Vancouver. He is president of the Dutch Atherosclerosis Society and the National Scientific Committee on Familial Hypercholesterolemia.

Dr. Kastelein is published over 400 research papers in such journals as Nature, Genetics, The Lancet, New England Journal of Medicine, and JAMA.